Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 26-week Treatment, Multi-center, Randomized, Doubleblind, Double Dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Brief Summary: The purpose of this study is to compare the efficacy and safety/tolerability of indacaterol and glycopyrronium (QVA149) (fixed-dose combination) with fluticasone/salmeterol over a 26-week period in patients with moderate to severe COPD.


Options:
A: Arm Label: UMEC/ VI via NDPI + placebo ACCUHALER/DISKUS arm; Type: EXPERIMENTAL; Interventions: Drug: UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI, Drug: Placebo DISKUS | Arm Label: FSC via ACCUHALER/DISKUS + placebo NDPI arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS, Drug: Placebo NDPI | Intervention Type: DRUG; Name: UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI; Assigned to Arm(s): UMEC/ VI via NDPI + placebo ACCUHALER/DISKUS arm | Intervention Type: DRUG; Name: FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS; Assigned to Arm(s): FSC via ACCUHALER/DISKUS + placebo NDPI arm | Intervention Type: DRUG; Name: Placebo DISKUS; Assigned to Arm(s): UMEC/ VI via NDPI + placebo ACCUHALER/DISKUS arm | Intervention Type: DRUG; Name: Placebo NDPI; Assigned to Arm(s): FSC via ACCUHALER/DISKUS + placebo NDPI arm
B: Arm Label: Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium bromide/Vilanterol, Drug: Placebo ACCUHALER/DISKUS | Arm Label: Fluticasone propionate/Salmeterol + placebo NDPI; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/Salmeterol, Drug: Placebo NDPI | Intervention Type: DRUG; Name: Umeclidinium bromide/Vilanterol; Assigned to Arm(s): Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS | Intervention Type: DRUG; Name: Placebo ACCUHALER/DISKUS; Assigned to Arm(s): Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS | Intervention Type: DRUG; Name: Fluticasone propionate/Salmeterol; Assigned to Arm(s): Fluticasone propionate/Salmeterol + placebo NDPI | Intervention Type: DRUG; Name: Placebo NDPI; Assigned to Arm(s): Fluticasone propionate/Salmeterol + placebo NDPI
C: Intervention Type: DRUG; Name: Tiotropium plus Salmeterol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluticasone/Salmeterol; Assigned to Arm(s): N/A
D: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: indacaterol and glycopyrronium (QVA149), Drug: Placebo to fluticasone/salmeterol | Arm Label: fluticasone/salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone/salmeterol, Drug: Placebo to indacaterol and glycopyrronium (QVA149) | Intervention Type: DRUG; Name: indacaterol and glycopyrronium (QVA149); Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Placebo to fluticasone/salmeterol; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: fluticasone/salmeterol; Assigned to Arm(s): fluticasone/salmeterol | Intervention Type: DRUG; Name: Placebo to indacaterol and glycopyrronium (QVA149); Assigned to Arm(s): fluticasone/salmeterol

Answer: D